Physician profile
James L Chiu
NPI 1124347265
$1,658,080.05
in general payments reported to CMS, 2019-2025
31 companies · $510K in 2025
The $510K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180K · 2020: $113K · 2021: $83K · 2022: $106K · 2023: $278K · 2024: $389K · 2025: $510K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $850K · Travel and Lodging: $128K · Honoraria: $98K · Consulting Fee: $68K · Food and Beverage: $31K · Education: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $850,303.50 |
| Travel and Lodging | $128,481.09 |
| Honoraria | $97,925.00 |
| Consulting Fee | $68,155.00 |
| Food and Beverage | $31,384.17 |
| Education | $335.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $265,747.50 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $237,095.55 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $217,189.19 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $191,290.86 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Axsome Therapeutics, INC. | $173,740.65 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $150,082.26 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $136,023.91 | 2021-2025 | Vraylar |
| E.R. Squibb & Sons, L.L.C. | $99,246.37 | 2024-2025 | Cobenfy |
| Allergan, INC. | $93,240.23 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $79,262.45 | 2021-2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $12,441.08 | 2022-2025 | Quviviq, Quviviq |
| Neuronetics, INC. | $1,019.98 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $284.00 | 2022-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $265.91 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $246.14 | 2019-2025 | Rexulti |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $136.75 | 2023-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $116.03 | 2019-2025 | Trintellix |
| Almatica Pharma LLC | $98.02 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Merck Sharp & Dohme LLC | $87.84 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $79.55 | 2019-2022 | |
| Tris Pharma INC | $68.64 | 2023-2024 | Dyanavel Xr |
| Avanir Pharmaceuticals, INC. | $53.56 | 2019 | |
| Sage Therapeutics, LLC | $49.46 | 2024 | |
| Corium, LLC | $48.79 | 2023-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $46.93 | 2022-2024 | |
| Noven Therapeutics, LLC | $24.83 | 2025 | Xelstrym |
| Sunovion Pharmaceuticals INC. | $24.09 | 2022 | |
| Collegium Pharmaceutical, INC. | $21.36 | 2025 | Jornay Pm |
| Eisai INC. | $17.81 | 2020 | |
| Adlon Therapeutics L.P. | $16.17 | 2021 | |
| Jazz Pharmaceuticals INC. | $14.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.